We’re in the first week of the second Trump administration, and it’s becoming clearer how it might impact healthcare ...

Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

Catalent to make Galapagos' CAR-T therapy, Kindeva gets $129M DuoDote contract, Solarbiotech/GPC Bio/Eleszto merge, Afrigen ...

FDA adds boxed warning to Teva's Copaxone and generic versions after serious allergic reactions, including anaphylaxis that ...

The FDA dodged claims from Vanda Pharmaceuticals that it allegedly violated the US Constitution by recommending the same drug ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

FDA delays Stealth BioTherapeutics' elamipretide decision to April 29; Valneva's Ixchiq succeeds in child safety trial; TargetRx raises $50M; Ab&B Bio-Tech files for HKEX IPO ...

Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all that, but finds itself navigating ...

AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says it’s dealing with a whole different set of ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...